Cargando…
SAT413 Feminising Gender Affirming Hormone Therapy Prolongs QTc Interval
Disclosure: L. Angus: Speaker; Self; Kirin Brewery. T. Lin: None. S. Leemaqz: None. M. Grossmann: None. J.D. Zajac: None. A.S. Cheung: None. Background: In trans people using feminising hormone therapy there is an increased risk of cardiovascular events including conduction disorders. It is known th...
Autores principales: | Angus, Lachlan, Lin, Tina, Leemaqz, Shalem, Grossmann, Mathis, Zajac, Jeffrey D, Cheung, Ada S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554701/ http://dx.doi.org/10.1210/jendso/bvad114.2084 |
Ejemplares similares
-
SAT644 Gender Affirming Hormone Therapy (GHAT) In Adult Male-to-female Mice Increases Cortical And Trabecular Bone, Resulting In An Increase In Bone Strength
por: Zajac, Jeffrey D, et al.
Publicado: (2023) -
Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
por: Nolan, Brendan J, et al.
Publicado: (2022) -
SAT412 Effects Of Gender-Affirming Hormone Therapy On The Connectivity Of Intrinsic Brain Networks
por: Pedreira, Clarissa C, et al.
Publicado: (2023) -
SAT402 A Multimodal Curriculum To Improve Medical Student Gender-affirming Communication Skills
por: Jones, Robert Benson, et al.
Publicado: (2023) -
SAT411 The Influence Of Gender Affirming Hormone Therapy On Markers Of Platelet Activation In Transgender Women
por: van Zijverden, L Mees, et al.
Publicado: (2023)